Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

The direct and indirect costs among U.S. privately insured employees with hypogonadism.

Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.

J Sex Med. 2012 Sep;9(9):2438-47. doi: 10.1111/j.1743-6109.2012.02810.x. Epub 2012 Jun 27.

PMID:
22738380
2.

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.

Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

J Med Econ. 2015 Jun;18(6):447-56. doi: 10.3111/13696998.2015.1021353. Epub 2015 Mar 27.

PMID:
25728698
3.

Direct and indirect costs associated with Dupuytren's contracture.

Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

J Med Econ. 2012;15(4):664-71. doi: 10.3111/13696998.2012.670678. Epub 2012 Mar 21.

PMID:
22369346
4.

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.

Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

Pharmacoeconomics. 2009;27(8):681-91. doi: 10.2165/11314700-000000000-00000.

PMID:
19712010
5.

Duloxetine use in chronic low back pain: treatment patterns and costs.

Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Pharmacoeconomics. 2012 Jul 1;30(7):595-609. doi: 10.2165/11598130-000000000-00000.

PMID:
22686662
6.

Economic burden of epilepsy among the privately insured in the US.

Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

Pharmacoeconomics. 2010;28(8):675-85. doi: 10.2165/11535570-000000000-00000.

PMID:
20623993
7.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Pharmacoeconomics. 2010;28(5):395-409. doi: 10.2165/11531040-000000000-00000.

PMID:
20402541
8.

Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.

Doshi JA, Cai Q, Buono JL, Spalding WM, Sarocco P, Tan H, Stephenson JJ, Carson RT.

J Manag Care Spec Pharm. 2014 Apr;20(4):382-90.

9.

Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.

Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

Epilepsia. 2010 May;51(5):838-44. doi: 10.1111/j.1528-1167.2009.02422.x. Epub 2009 Dec 7.

10.

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.

Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

Curr Med Res Opin. 2009 Apr;25(4):869-77. doi: 10.1185/03007990902743869 .

PMID:
19232041
11.

United States comparative costs and absenteeism of diabetic ophthalmic conditions.

Brook RA, Kleinman NL, Patel S, Smeeding JE, Beren IA, Turpcu A.

Postgrad Med. 2015 Jun;127(5):455-62. doi: 10.1080/00325481.2014.994468. Epub 2014 Dec 31.

PMID:
25549691
12.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.

Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

J Med Econ. 2012;15(3):601-9. doi: 10.3111/13696998.2012.667027. Epub 2012 Mar 1.

PMID:
22376190
13.

The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings.

Black J, Reaven NL, Funk SE, McGaughey K, Ohayon M, Guilleminault C, Ruoff C, Mignot E.

Sleep Med. 2014 May;15(5):522-9. doi: 10.1016/j.sleep.2014.02.001. Epub 2014 Feb 15.

PMID:
24768358
14.

The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings.

Gore M, Sadosky A, Stacey BR, Tai KS, Leslie D.

Spine (Phila Pa 1976). 2012 May 15;37(11):E668-77. doi: 10.1097/BRS.0b013e318241e5de.

PMID:
22146287
15.

All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.

Asche CV, Singer ME, Jhaveri M, Chung H, Miller A.

J Manag Care Pharm. 2010 Nov-Dec;16(9):703-12.

16.

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.

White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

J Occup Environ Med. 2008 Jan;50(1):13-24. doi: 10.1097/JOM.0b013e31815cff4b.

PMID:
18188077
17.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
18.

Health and disability costs of depressive illness in a major U.S. corporation.

Druss BG, Rosenheck RA, Sledge WH.

Am J Psychiatry. 2000 Aug;157(8):1274-8.

PMID:
10910790
19.

Economic burden of back and neck pain: effect of a neuropathic component.

Kleinman N, Patel AA, Benson C, Macario A, Kim M, Biondi DM.

Popul Health Manag. 2014 Aug;17(4):224-32. doi: 10.1089/pop.2013.0071. Epub 2014 Mar 31.

PMID:
24684443
20.

Costs and absence of HCV-infected employees by disease stage.

Baran RW, Samp JC, Walker DR, Smeeding JE, Young JW, Kleinman NL, Brook RA.

J Med Econ. 2015;18(9):691-703. doi: 10.3111/13696998.2015.1045423. Epub 2015 Jun 11.

PMID:
26047262
Items per page

Supplemental Content

Write to the Help Desk